Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 1/20 | 0.59 |
| ▸ | BCR | P11274 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.58 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.56 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.55 |
| ▸ | TUBB1 | Q9H4B7 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MET | P08581 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29603846 | 1.00 | ABL1 (0.59) | ABL1BCRCYP3A4CYP2B6CYP1A2 | |
| SCHEMBL1457517 | 1.00 | ABL1 (0.59) | ABL1BCRCYP3A4CYP2B6CYP1A2 | |
| SCHEMBL4632508 | 0.93 | TUBB1 (0.56) | ABL1BCRCYP3A4CYP2B6CYP1A2 | |
| SCHEMBL152269 | 0.93 | TUBB1 (0.56) | ABL1BCRCYP3A4CYP2B6CYP1A2 | |
| SCHEMBL13176833 | 0.90 | PTGS1 (0.54) | ABL1BCRCYP3A4CYP2B6CYP1A2 | |
| SCHEMBL12060517 | 0.88 | ALOX5 (0.49) | ABL1BCRCYP3A4CYP2B6CYP1A2 | |
| SCHEMBL18014933 | 0.88 | ALOX5 (0.49) | ABL1BCRCYP3A4CYP2B6CYP1A2 | |
| Adonitol SCHEMBL29089823 | 0.87 | ABL1 (0.47) | ABL1BCRCYP3A4CYP2B6CYP1A2 | |
| SCHEMBL30887916 | 0.86 | CYP1A1 (0.58) | CYP1A2PTGS1TUBB1MAPTGAA | |
| SCHEMBL4299632 | 0.86 | CYP1A1 (0.58) | CYP1A2PTGS1TUBB1MAPTGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1462 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122081253-A | Laccase mutant and application thereof | — | 2026-05-26 | — | — | CN | claimed |
| US-20260125609-A1 | BIO-BASED ADDITIVES FOR DIESEL | SIXRING INC (CA) | 2026-05-07 | — | — | US | claimed |
| WO-2025242792-A1 | AQUEOUS MINERAL FIBRE BINDER COMPOSITION BASED ON ONE OR MORE PROTEINS, A METHOD FOR MAKING MINERAL FIBRE PRODUCTS AND USE THEREOF | ROCKWOOL A/S (DK) | 2025-11-27 | — | — | WO | claimed |
| EP-3341487-B1 | MEANS AND METHODS FOR PRODUCTION OF ORGANIC COMPOUNDS | UNIV SAARLAND (DE) | 2025-10-01 | — | — | EP | claimed |
| EP-3720926-B1 | RECOVERY PROCESS FOR HIGH PRESSURE PROCESSING SYSTEM | STEEPER ENERGY APS (DK) | 2025-09-17 | — | — | EP | claimed |
| US-20250270160-A1 | Processes for the Production of Vanillin and Related Compounds | UNIV LJUBLJANI (SI) | 2025-08-28 | — | — | US | claimed |
| US-12344748-B2 | Carbon black from biomass | NORSE BIOTECH AS (NO) | 2025-07-01 | — | — | US | claimed |
| WO-2025064839-A1 | COMPOSITIONS AND METHODS RELATED TO THE SIMULTANEOUS MANUFACTURE AND PURIFICATION OF FLAVOR AND FRAGRANCE MOLECULES | Natural Extraction Systems, LLC (US) | 2025-03-27 | — | — | WO | claimed |
| CN-119529238-A | All-biological-based glass polymer material capable of being recycled in closed loop, and preparation method, recycling method and application thereof | 北京林业大学 | 2025-02-28 | — | — | CN | claimed |
| CN-113396332-B | Method for evaluating pregnancy progression and premature abortion for clinical intervention and use thereof | 斯坦福大学托管董事会 | 2025-02-11 | — | — | CN | claimed |
| EP-3649184-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2020-05-13 | — | — | EP | claimed |
| EP-3649183-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2020-05-13 | — | — | EP | claimed |
| WO-2019010263-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2019-01-10 | — | — | WO | claimed |
| WO-2019010265-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2019-01-10 | — | — | WO | claimed |
| US-20190010293-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2019-01-10 | — | — | US | claimed |
| US-20190010427-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2019-01-10 | — | — | US | claimed |
| EP-1341503-B1 | AGENT AND METHOD FOR DYEING KERATIN FIBRES | WELLA AG (DE) | 2008-02-13 | — | — | EP | claimed |
| EP-1341503-A2 | AGENT AND METHOD FOR DYEING KERATIN FIBRES | Wella Aktiengesellschaft (DE) | 2003-09-10 | — | — | EP | claimed |
| US-20030041391-A1 | Agent and method for dyeing keratin fibres | Wella GmbH (DE) | 2003-03-06 | — | — | US | claimed |
| WO-2002047633-A2 | AGENT AND METHOD FOR DYEING KERATIN FIBRES | WELLA AKTIENGESELLSCHAFT (DE) | 2002-06-20 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250270160-A1 | Processes for the Production of Vanillin and Related Compounds | VAT1, NOX4, NQO1 | ABL1 739/4885BCR 433/4885CYP3A4 36/4885 |
| US-20260125609-A1 | BIO-BASED ADDITIVES FOR DIESEL | SORD, DBF4, MLYCD | ABL1 4864/4885BCR 2302/4885CYP3A4 109/4885 |
| US-20030041391-A1 | Agent and method for dyeing keratin fibres | KRT18, AKR7A2, ADH5 | ABL1 3084/4885BCR 2430/4885CYP3A4 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.